0000000000144616

AUTHOR

Massimo Filippi

showing 20 related works from this author

Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.

2022

Background: Definitions for reliable identification of transition from relapsing-remitting multiple sclerosis (MS) to secondary progressive (SP)MS in clinical cohorts are not available. Objectives: To compare diagnostic performances of two different data-driven SPMS definitions. Methods: Data-driven SPMS definitions based on a version of Lorscheider’s algorithm (DDA) and on the EXPAND trial inclusion criteria were compared, using the neurologist’s definition (ND) as gold standard, in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), Akaike information criterion (AIC) and area under the curve (AUC). Results: A cohort of 10,240 MS patients wi…

Multiple SclerosisMultiple Sclerosis Chronic ProgressiveMultiple sclerosisMultiple Sclerosis Relapsing-RemittingNeurologybig dataArea Under Curvedata-driven algorithmdisease registrysecondary progressiveHumansSettore MED/26 - NeurologiaNeurology (clinical)prognosisMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Power estimation for non-standardized multisite studies

2016

A concern for researchers planning multisite studies is that scanner and T1-weighted sequence-related biases on regional volumes could overshadow true effects, especially for studies with a heterogeneous set of scanners and sequences. Current approaches attempt to harmonize data by standardizing hardware, pulse sequences, and protocols, or by calibrating across sites using phantom-based corrections to ensure the same raw image intensities. We propose to avoid harmonization and phantom-based correction entirely. We hypothesized that the bias of estimated regional volumes is scaled between sites due to the contrast and gradient distortion differences between scanners and sequences. Given this…

Computer scienceCognitive Neurosciencecomputer.software_genreSensitivity and Specificity050105 experimental psychologyImaging phantomArticleSet (abstract data type)03 medical and health sciences0302 clinical medicineDistortionImage Interpretation Computer-AssistedCalibrationmedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumans0501 psychology and cognitive sciencesSegmentationComputer Simulation10. No inequalityScalingModels Statisticalmedicine.diagnostic_test05 social sciencesContrast (statistics)BrainReproducibility of ResultsMagnetic resonance imagingEquipment DesignScale factorImage EnhancementMagnetic Resonance ImagingUnited StatesEquipment Failure AnalysisEuropeNeurologyOrdinary least squaresData miningFunction and Dysfunction of the Nervous SystemArtifactscomputer030217 neurology & neurosurgeryAlgorithms
researchProduct

Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study

2022

Portaccio et al. report that in early relapsing-onset multiple sclerosis, progression independent of relapse activity is an important contributor to disability accumulation. Insidious progression occurs even in the earliest disease phases, suggesting that inflammation and degeneration may represent a single disease continuum.Disability accrual in multiple sclerosis may occur as relapse-associated worsening or progression independent of relapse activity. The role of progression independent of relapse activity in early multiple sclerosis is yet to be established. The objective of this multicentre, observational, retrospective cohort study was to investigate the contribution of relapse-associa…

Multiple Sclerosisrelapse-associated worseningprogression independent of relapse activityrelapsing multiple sclerosisCohort StudiesMultiple Sclerosis Relapsing-Remittingrelapse associated worseningRecurrenceChronic DiseaseDisease ProgressionHumansSettore MED/26 - NeurologiaNeurology (clinical)Retrospective Studies
researchProduct

Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis

2021

Importance Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging. Objective To evaluate changes in the prognosis of POMS over time in association with changes in therapeutic and managing standards. Design, Setting, and Participants Retrospective, multicenter, observational study. Data were extracted and collected in May 2019 from the Italian MS Registry, a digital database including more than 59 000 patients. Inclusion criteria were…

MaleRegistriePediatricsAdolescent; Adult; Age of Onset; Aged; Child; Child Preschool; Female; Humans; Italy; Male; Middle Aged; Multiple Sclerosis; Registries; Retrospective Studies; Risk Factors; Young Adult; Disabled Persons; Disease ProgressionRisk of Disability0302 clinical medicineRisk FactorsRetrospective StudieMultiple Sclerosi030212 general & internal medicineRegistriesAge of OnsetChildOriginal InvestigationHazard ratioConfoundingMiddle Agedpediatric-onset MS (POMS)Italytherapeutic and managing standardsChild PreschoolDisease ProgressionSettore MED/26 - NeurologiaFemaleDisabled PersonHumanAdultmedicine.medical_specialtyMultiple SclerosisAdolescentMEDLINEProfile of mood states03 medical and health sciencesYoung AdultmedicineHumansIn patientDisabled PersonsPreschoolpediatric-onset MS (POMS) therapeutic and managing standardsRetrospective StudiesAgedExpanded Disability Status Scalebusiness.industryPediatric-Onset Multiple SclerosisMultiple sclerosisRisk Factormedicine.diseaseObservational studyNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.

2021

Objective: To identify baseline factors associated with disease activity in patients with relapsing–remitting multiple sclerosis (RRMS) under teriflunomide treatment. Methods: This was an independent, multi-centre, retrospective post-marketing study. We analysed data of 1,507 patients who started teriflunomide since October 2014 and were regularly followed in 28 Centres in Italy. We reported the proportions of patients who discontinued treatment (after excluding 32 lost to follow-up) and who experienced clinical disease activity, i.e., relapse(s) and/or confirmed disability worsening, as assessed by the Expanded Disability Status Scale (EDSS). Decision tree-based analysis was performed to i…

medicine.medical_specialtyNeurologyMultiple SclerosisToluidinesHydroxybutyratesOral drugsDiseaseRelapsing-RemittingSettore MED/26Pregnancy planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideTeriflunomideNitrilesmedicineHumans030212 general & internal medicineAdverse effectRetrospective StudiesExpanded Disability Status Scalebusiness.industryMultiple sclerosismedicine.diseaseSettore MED/26 - NEUROLOGIANeurologychemistryTolerabilityItalyMultiple sclerosis; Oral drugs; Teriflunomide; Crotonates; Humans; Hydroxybutyrates; Italy; Nitriles; Retrospective Studies; Toluidines; Multiple Sclerosis; Multiple Sclerosis Relapsing-RemittingCrotonatesNeurology (clinical)business030217 neurology & neurosurgeryJournal of neurology
researchProduct

Behavioral and psychological effects of coronavirus disease-19 quarantine in patients with dementia

2020

Background: In March 2020, the World Health Organization declared a global pandemic due to the novel coronavirus SARS-CoV-2 and several governments planned a national quarantine in order to control the virus spread. Acute psychological effects of quarantine in frail elderly subjects with special needs, such as patients with dementia, have been poorly investigated. The aim of this study was to assess modifications of neuropsychiatric symptoms during quarantine in patients with dementia and their caregivers. Methods: This is a sub-study of a multicenter nation-wide survey. A structured telephone interview was delivered to family caregivers of patients with diagnosis of Alzheimer disease (AD),…

Pediatricsmedicine.medical_specialtylcsh:RC435-571IrritabilityBehavioral symptoms03 medical and health sciences0302 clinical medicinelcsh:PsychiatryPsychological symptomsmedicineDementiaApathyVascular dementiaBehavioral and psychological symptoms Behavioral symptoms Caregiver Coronavirus disease Dementia Gender Psychological symptoms QuarantineOriginal ResearchMED/26 - NEUROLOGIAPsychiatryBehavioral symptomDementia with Lewy bodiesFamily caregiversbusiness.industryBehavioral and psychological symptomsGenderBehavioral and psychological symptomCaregiver burdenmedicine.diseaseMultiinfarct dementiaCaregiver030227 psychiatryCoronavirus diseaseBehavioral and psychological symptoms; Behavioral symptoms; Caregiver; Coronavirus disease; Dementia; Gender; Psychological symptoms; QuarantinePsychiatry and Mental healthSettore MED/26 - NEUROLOGIAMED/17 - MALATTIE INFETTIVEQuarantineMED/25 - PSICHIATRIADementiaM-PSI/08 - PSICOLOGIA CLINICAPsychological symptommedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Clinical Efficacy of Laquinimod for the Treatment of Multiple Sclerosis; Pooled Analyses from the ALLEGRO and BRAVO Phase III Trials (S01.007)

2012

Objective: The current report provides detail on pooled analyses assessing the effect of laquinimod on relapse, disability, and brain atrophy measures from the recently completed phase III trials ALLEGRO and BRAVO. Background Laquinimod is an oral, CNS acting immunomodulator in development for the treatment of multiple sclerosis. Its impact on disability progression and brain atrophy, two indices of longterm outcome for patients with multiple sclerosis (MS) are being studied in its phase III trials. Design/Methods: MS patients (N=2437) were randomized to laquinimod (n=984) or placebo (n = 1006). In both trials, patients underwent neurological examinations including the Expanded Disability S…

medicine.medical_specialtyPhase iii trialsbusiness.industryRelapse ratePharmacologyClinical trialSafety profilechemistry.chemical_compoundchemistryFamily medicineMedicinemedia_common.cataloged_instanceDisability progressionNeurology (clinical)Clinical efficacyEuropean unionbusinessLaquinimodmedia_commonNeurology
researchProduct

Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study

2022

Background and ObjectivesSeveral studies have assessed risk factors associated with the severity of COVID-19 outcomes in people with multiple sclerosis (PwMS). The potential role of disease-modifying therapies (DMTs) and demographic and clinical factors on the risk of acquiring SARS-CoV-2 infection has not been evaluated so far. The objective of this study was to assess risk factors of contracting SARS-CoV-2 infection in PwMS by using data collected in the Italian MS Register (IMSR).MethodsA case-control (1:2) study was set up. Cases included PwMS with a confirmed diagnosis of COVID-19, and controls included PwMS without a confirmed diagnosis of COVID-19. Both groups were propensity score–m…

AdultMaleMultiple SclerosisTime Factors41Dimethyl FumarateSex FactorRelapsing-RemittingSeverity of Illness IndexArticleImmunosuppressive AgentSex FactorsMultiple Sclerosis Relapsing-RemittingRisk FactorsMultiple SclerosiOdds RatioHumansAge Factor36053g COVID-19Fingolimod HydrochlorideSARS-CoV-2NatalizumabRisk FactorAge FactorsCOVID-19Glatiramer AcetateInterferon-betaMiddle AgedMultiple Sclerosis Chronic Progressive323Chronic ProgressiveNeurologyItalyCase-Control StudiesAdult; Age Factors; COVID-19; Case-Control Studies; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Odds Ratio; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors; Time FactorsFemaleNeurology (clinical)Case-Control StudieImmunosuppressive AgentsHuman
researchProduct

Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register

2021

AbstractThe current study aims to compare injectable and oral first-line disease-modifying therapies (DMTs) for time to first relapse, time to confirmed disability progression (CDP), and time to discontinuation using a cohort of relapsing remitting multiple sclerosis (RRMS) patients, with data extracted from the Italian MS Register. This multicenter, observational, retrospectively acquired, and propensity-adjusted cohort study utilized RRMS-naïve patients from the Italian MS Register who started either injectable or oral first-line DMTs between January 1, 2010, and December 31, 2017, to evaluate the impact on disability outcomes in patients. Enrolled patients were divided into two groups, n…

Maleoral DMTsoral DMTAdministration OralDiseaseRelapsing-RemittingCohort Studies0302 clinical medicineImmunologicinjectable DMTPharmacology (medical)030212 general & internal medicineRegistriesSubcutaneousMiddle AgedItalyEDSS score; injectable DMTs; Multiple sclerosis; oral DMTs; real-world setting; Adjuvants Immunologic; Administration Oral; Adult; Cohort Studies; Female; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Injections Subcutaneous; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; RegistriesAdministrationCohortSettore MED/26 - NeurologiaOriginal ArticleFemaleNeurosurgeryCohort studyOralAdultmedicine.medical_specialtyEDSS scoreInjections SubcutaneousLower riskInjectionsMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicInternal medicinereal-world settingmedicineHumansImmunologic FactorsMultiple sclerosiAdjuvantsinjectable DMTsRetrospective StudiesPharmacologybusiness.industryMultiple sclerosisGlatiramer AcetateInterferon-betamedicine.diseaseDiscontinuationObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Tract-specific white matter structural disruption in patients with bipolar disorder

2011

Benedetti F, Absinta M, Rocca MA, Radaelli D, Poletti S, Bernasconi A, Dallaspezia S, Pagani E, Falini A, Copetti M, Colombo C, Comi G, Smeraldi E, Filippi M. Tract-specific white matter structural disruption in patients with bipolar disorder. Bipolar Disord 2011: 13: 414–424. © 2011 The Authors. Journal compilation © 2011 John Wiley & Sons A/S. Objectives:  A growing body of evidence suggests that, independent of localized brain lesions, mood disorders can be associated with dysfunction of brain networks involved in the modulation of emotional and cognitive behavior. We used diffusion tensor (DT) tractography to quantify the presence and extent of structural injury to the connections betwe…

Cingulate cortexmedicine.diseaseBrain mapping030227 psychiatry3. Good healthWhite matter03 medical and health sciencesPsychiatry and Mental health0302 clinical medicinemedicine.anatomical_structurePosterior cingulateFractional anisotropymedicineMajor depressive disorderBipolar disorderPsychologyNeuroscience030217 neurology & neurosurgeryBiological PsychiatryTractographyBipolar Disorders
researchProduct

P2‐401: Reliability of DTI: A european multicenter study

2010

Psychiatry and Mental healthCellular and Molecular NeuroscienceDevelopmental NeuroscienceMulticenter studyEpidemiologyComputer scienceHealth PolicyNeurology (clinical)Geriatrics and GerontologyReliability (statistics)Reliability engineeringAlzheimer's & Dementia
researchProduct

Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies

2021

Background and aims: No consensus exists on how aggressively to treat relapsing–remitting multiple sclerosis (RRMS) nor on the timing of the treatment. The objective of this study was to evaluate disability trajectories in RRMS patients treated with an early intensive treatment (EIT) or with a moderate-efficacy treatment followed by escalation to higher-efficacy disease modifying therapy (ESC). Methods: RRMS patients with ⩾5-year follow-up and ⩾3 visits after disease modifying therapy (DMT) start were selected from the Italian MS Registry. EIT group included patients who received as first DMT fingolimod, natalizumab, mitoxantrone, alemtuzumab, ocrelizumab, cladribine. ESC group patients rec…

Pediatricsmedicine.medical_specialtybig data; disability trajectories; disease registry; multiple sclerosis.multiple sclerosis03 medical and health sciences0302 clinical medicineDisease registrybig dataMedicine030212 general & internal medicineRC346-429Original Researchbig data; disability trajectories; disease registry; multiple sclerosisPharmacologybusiness.industryMultiple sclerosisLong term disabilitymedicine.diseaseNeurologydisease registryTreatment strategySettore MED/26 - Neurologiadisability trajectoriesNeurology. Diseases of the nervous systemNeurology (clinical)business030217 neurology & neurosurgeryTherapeutic Advances in Neurological Disorders
researchProduct

MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central …

2021

Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of myeloid differentiation primary response (88) (MYD88) L265P mutation (mut-MYD88) and interleukin-10 (IL-10) in cerebrospinal fluid (CSF) of both patients with newly diagnosed (n = 36) and relapsed (n = 27) PCNSL and 162 controls (118 CNS disorders and 44 extra-CNS lymphomas). The concordance of MYD88 mutational status between tumour tissue and CSF sample and the source of ILs in PCNSL tissues were also investigated. Mut-MYD88 was assessed by TaqMan-based polymerase chain reac…

AdultMalePathologymedicine.medical_specialtyLymphomaBiopsyConcordanceinterleukin-10diffuse large B-cell lymphomaMutation MissenseCentral Nervous System Neoplasms03 medical and health sciencesprimary CNS lymphoma0302 clinical medicineCerebrospinal fluidhemic and lymphatic diseasesBiopsyBiomarkers TumorTaqManmedicineHumansdiffuse large B-cell lymphoma interleukin-10 interleukin-6 MYD88 L265P mutation primary CNS lymphomaProspective cohort studyAgedmedicine.diagnostic_testbusiness.industryinterleukin-6Primary central nervous system lymphomaHematologyMiddle Agedmedicine.diseaseInterleukin-10Neoplasm ProteinsLymphomaMYD88 L265P mutationAmino Acid Substitution030220 oncology & carcinogenesisMyeloid Differentiation Factor 88FemalebusinessDiffuse large B-cell lymphoma030215 immunologyBritish Journal of Haematology
researchProduct

The Impact of COVID-19 Quarantine on Patients With Dementia and Family Caregivers: A Nation-Wide Survey

2021

IntroductionPrevious studies showed that quarantine for pandemic diseases is associated with several psychological and medical effects. The consequences of quarantine for COVID-19 pandemic in patients with dementia are unknown. We investigated the clinical changes in patients with Alzheimer’s disease and other dementias, and evaluated caregivers’ distress during COVID-19 quarantine.MethodsThe study involved 87 Italian Dementia Centers. Patients with Alzheimer’s Disease (AD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementia (FTD), and Vascular Dementia (VD) were eligible for the study. Family caregivers of patients with dementia were interviewed by phone in April 2020, 45 days after …

AgingPediatricsmedicine.medical_specialtyCognitive Neurosciencelcsh:RC321-57103 medical and health sciences0302 clinical medicinemental disordersAlzheimer’s disease BPSD caregiver burden COVID-19 dementia quarantinemedicineDementiaBPSD030212 general & internal medicineVascular dementialcsh:Neurosciences. Biological psychiatry. NeuropsychiatryAlzheimer’s disease; BPSD; caregiver burden; COVID-19; dementia; quarantineDepression (differential diagnoses)Original ResearchM-PSI/05 - PSICOLOGIA SOCIALEMED/26 - NEUROLOGIAcaregiver burdenDementia with Lewy bodiesFamily caregiversbusiness.industryquarantineCOVID-19Odds ratiomedicine.diseaseSettore MED/26 - NEUROLOGIADistressMED/17 - MALATTIE INFETTIVEbusinessAlzheimer’s disease030217 neurology & neurosurgeryNeuroscienceFrontotemporal dementiadementia
researchProduct

Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors

2021

Background: No uniform criteria for a sensitive identification of the transition from relapsing–remitting multiple sclerosis (MS) to secondary-progressive multiple sclerosis (SPMS) are available. Objective: To compare risk factors of SPMS using two definitions: one based on the neurologist judgment (ND) and an objective data-driven algorithm (DDA). Methods: Relapsing-onset MS patients ( n = 19,318) were extracted from the Italian MS Registry. Risk factors for SPMS and for reaching irreversible Expanded Disability Status Scale (EDSS) 6.0, after SP transition, were estimated using multivariable Cox regression models. Results: SPMS identified by the DDA ( n = 2343, 12.1%) were older, more disa…

Oncologymedicine.medical_specialtyRelapsing-RemittingMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineDisease registryRecurrenceRisk Factorsbig dataInternal medicinemedicineHumansdata-driven algorithmMultiple sclerosi030212 general & internal medicinebig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressive; Disease Progression; Humans; Recurrence; Risk Factors; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-RemittingSecondary progressiveTransition (genetics)business.industryMultiple sclerosisMultiple Sclerosis Chronic Progressivemedicine.diseaseChronic ProgressiveNeurologybig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressiveDisease Progressiondisease registrysecondary progressiveSettore MED/26 - NeurologiaNeurology (clinical)prognosisbusinessprognosi030217 neurology & neurosurgery
researchProduct

Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis

2022

Objective: This study was undertaken to describe and compare disease course and prognosis of early (ie, disease onset before age 11 years) and late (ie, disease onset after age 11 years) onset pediatric multiple sclerosis. Methods: Prospectively collected clinical information from Italian Multiple Sclerosis Register of 1993 pediatric multiple sclerosis patients, of whom 172 had early onset, was analyzed. Cox models adjusted for sex, baseline Expanded Disability Status Scale score, and disease-modifying treatments and stratified for diagnostic criteria adopted (Poser vs McDonald) were used to assess the risk of reaching irreversible Expanded Disability Status Scale scores of 3, 4, and 6, and…

MaleNatural History of Multiple SclerosisMultiple SclerosisNeurologyRecurrencePediatric Multiple SclerosisDisease ProgressionHumansDisabled PersonsSettore MED/26 - NeurologiaNeurology (clinical)ChildPrognosis
researchProduct

Multicenter stability of diffusion tensor imaging measures: a European clinical and physical phantom study.

2011

Diffusion tensor imaging (DTI) detects white matter damage in neuro-psychiatric disorders, but data on reliability of DTI measures across more than two scanners are still missing. In this study we assessed multicenter reproducibility of DTI acquisitions based on a physical phantom as well as brain scans across 16 scanners. In addition, we performed DTI scans in a group of 26 patients with clinically probable Alzheimer's disease (AD) and 12 healthy elderly controls at one single center. We determined the variability of fractional anisotropy (FA) measures using manually placed regions of interest as well as automated tract based spatial statistics and deformation based analysis. The coefficie…

Coefficient of variationNeuroscience (miscellaneous)Nerve Fibers MyelinatedBrain mappingImaging phantommethods [Diffusion Tensor Imaging]White matterYoung AdultNeuroimagingBiasAlzheimer Diseasepathology [Brain]Fractional anisotropymedicineHumansRadiology Nuclear Medicine and imagingddc:610AgedAged 80 and overReproducibilityBrain Mappingpathology [Nerve Fibers Myelinated]business.industryPhantoms Imagingdiagnosis [Alzheimer Disease]BrainMiddle AgedEuropePsychiatry and Mental healthDiffusion Tensor Imagingmedicine.anatomical_structureAnisotropyFemaleNuclear medicinebusinessPsychologyDiffusion MRI
researchProduct

Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria

2018

MRI has been formally included in the diagnostic work-up of patients with a suspicion of multiple sclerosis (MS) in 2001, to demonstrate disease dissemination in space (DIS) and time (DIT) and to exclude alternative diagnoses.1 Over time, these criteria have been modified to simplify their use and to clarify specific aspects (eg, spinal cord findings).2 One aspect marginally analysed in the diagnostic work-up of patients with clinically isolated syndrome (CIS) is the role of intracortical lesions (ICLs), which are a prominent feature of MS and contribute to disability and cognitive impairment.2 A single-centre study3 showed that inclusion of ICL for the evaluation of DIS in CIS increased th…

AdultMalemedicine.medical_specialtyMultiple SclerosisTime Factorsmultiple sclerosis030218 nuclear medicine & medical imagingCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicineMedicineHumansMRI; multiple sclerosisProspective StudiesMedical diagnosisProspective cohort studymriCerebral CortexClinically isolated syndromemedicine.diagnostic_testbusiness.industryMultiple sclerosisBrainMagnetic resonance imagingMiddle Agedmedicine.diseaseInstitutional review boardMagnetic Resonance ImagingSurgeryPsychiatry and Mental healthSpinal CordCohortSurgeryFemaleNeurology (clinical)Radiologybusiness030217 neurology & neurosurgeryMRICohort studyDemyelinating Diseases
researchProduct

A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility

2022

Abstract Background Over 200 genetic loci have been associated with multiple sclerosis (MS) explaining ~ 50% of its heritability, suggesting that additional mechanisms may account for the “missing heritability” phenomenon. Objective To analyze a large cohort of Italian individuals to identify markers associated with MS with potential functional impact in the disease. Methods We studied 2571 MS and 3234 healthy controls (HC) of continental Italian origin. Discovery phase included a genome wide association study (1727 MS, 2258 HC), with SNPs selected according to their association in the Italian cohort only or in a meta-analysis of signals with a cohort of European ancestry (4088 MS, 7144 HC)…

NeurologyGenetics Genome-wide association study Multiple sclerosis Susceptibility TBKBP1Neurology (clinical)Journal of Neurology
researchProduct

Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

2023

Background and ObjectivesUncontrolled evidence suggests that autologous hematopoietic stem cell transplantation (AHSCT) can be effective in people with active secondary progressive multiple sclerosis (SPMS). In this study, we compared the effect of AHSCT with that of other anti-inflammatory disease-modifying therapies (DMTs) on long-term disability worsening in active SPMS.MethodsWe collected data from the Italian Bone Marrow Transplantation Study Group and the Italian Multiple Sclerosis Register. Patients were considered eligible if treatment had been started after the diagnosis of SPMS. Disability worsening was assessed by the cumulative proportion of patients with a 6-month confirmed dis…

Hematopoietic Stem Cell TransplantationActive Secondary Progressive Multiple SclerosisNeurology (clinical)Research Article
researchProduct